Cargando…

Targeted Discovery and Validation of Plasma Biomarkers of Parkinson’s Disease

[Image: see text] Despite extensive research, an unmet need remains for protein biomarkers of Parkinson’s disease (PD) in peripheral body fluids, especially blood, which is easily accessible clinically. The discovery of such biomarkers is challenging, however, due to the enormous complexity and huge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Catherine, Zhou, Yong, Dator, Romel, Ginghina, Carmen, Zhao, Yanchun, Movius, James, Peskind, Elaine, Zabetian, Cyrus P., Quinn, Joseph, Galasko, Douglas, Stewart, Tessandra, Shi, Min, Zhang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224986/ https://www.ncbi.nlm.nih.gov/pubmed/24853996 http://dx.doi.org/10.1021/pr500421v

Ejemplares similares

Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson’s disease pathogenesis
por: Sheng, Lifu, et al.
Publicado: (2020)

Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
por: Stewart, Tessandra, et al.
Publicado: (2015)

Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson’s Disease
por: Hossein-nezhad, Arash, et al.
Publicado: (2016)

DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease
por: Lin, Xiangmin, et al.
Publicado: (2012)

Premotor biomarkers for Parkinson's disease - a promising direction of research
por: Haas, Brian R, et al.
Publicado: (2012)

Predictive Modeling of Alzheimer’s and Parkinson’s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid
por: Hwangbo, Nathan, et al.
Publicado: (2022)

Combining clinical and biofluid markers for early Parkinson's disease detection
por: Yu, Zhenwei, et al.
Publicado: (2017)

Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region
por: Hill-Burns, Erin M., et al.
Publicado: (2011)

Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease
por: Perrin, Richard J., et al.
Publicado: (2011)

Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
por: Tian, Chen, et al.
Publicado: (2019)

Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry
por: Kim, Hojoong M., et al.
Publicado: (2018)

Multiple Enzymatic Digestions and Ion Mobility Separation Improve Quantification of Bacterial Ribosomal Proteins by Data Independent Acquisition Liquid Chromatography−Mass Spectrometry
por: Dator, Romel P., et al.
Publicado: (2014)

Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease
por: Wallen, Zachary D., et al.
Publicado: (2018)

Exploring human-genome gut-microbiome interaction in Parkinson’s disease
por: Wallen, Zachary D., et al.
Publicado: (2021)

Identification of a novel Parkinson’s disease locus via stratified genome-wide association study
por: Hill-Burns, Erin M, et al.
Publicado: (2014)

Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems
por: Galasko, Douglas, et al.
Publicado: (2013)

Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson's Disease: A HuGE Review and Meta-Analysis
por: Ragland, Margaret, et al.
Publicado: (2009)

Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson Disease
por: Hamza, Taye H., et al.
Publicado: (2014)

Bioanalytical and Mass Spectrometric Methods for Aldehyde Profiling in Biological Fluids
por: Dator, Romel P., et al.
Publicado: (2019)

Resting-State Cerebello-Cortical Dysfunction in Parkinson's Disease
por: Palmer, William C., et al.
Publicado: (2021)

PNPLA6‐Related Disorder with Levodopa‐Responsive Parkinsonism
por: Kazanci, Serdar, et al.
Publicado: (2022)

SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers
por: Shea, Dylan, et al.
Publicado: (2022)

Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease
por: Tumas, Vitor, et al.
Publicado: (2016)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults
por: Li, Ge, et al.
Publicado: (2017)

Plasma and urine biomarkers in chronic kidney disease: closer to clinical application
por: Zabetian, Azadeh, et al.
Publicado: (2021)

Multivariate prediction of dementia in Parkinson’s disease
por: Phongpreecha, Thanaphong, et al.
Publicado: (2020)

Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts
por: Lawton, Michael, et al.
Publicado: (2022)

Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease
por: Martini, Douglas N., et al.
Publicado: (2020)

Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures
por: Kim, Hojoong M., et al.
Publicado: (2019)

Advancement of Biomarker Discovery and Validation through the HUPO Plasma Proteome Project
por: Omenn, Gilbert S.
Publicado: (2004)

An Integrated Quantitative Proteomics Workflow for Cancer Biomarker Discovery and Validation in Plasma
por: Kumar, Vipin, et al.
Publicado: (2020)

Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects
por: Li, Ge, et al.
Publicado: (2009)

Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
por: Santaella, Anna, et al.
Publicado: (2020)

Targeted High Resolution LC/MS(3) Adductomics Method for the Characterization of Endogenous DNA Damage
por: Carrà, Andrea, et al.
Publicado: (2019)

Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches
por: Galasko, Douglas
Publicado: (2015)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Cognition as a mediator for gait and balance impairments in GBA-related Parkinson’s disease
por: Morris, Rosie, et al.
Publicado: (2022)

Gait and balance in apolipoprotein Ɛ4 allele carriers in older adults and Parkinson’s disease
por: Morris, Rosie, et al.
Publicado: (2023)

Metabolomics Profiles of Smokers from Two Ethnic Groups with Differing Lung Cancer Risk
por: Dator, Romel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7nr4e49oo4n7h6v29c47f1gnlr